Evidence map›Paper›PMID 41493192›Full record

Trial reportInternational forum of allergy & rhinology2026

Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

Joaquim Mullol, Joseph K Han, Tanya M Laidlaw, Claire Hopkins, Anju T Peters, Oliver Pfaar, Martin Desrosiers, Stella E Lee, Andrew P Lane, Claudia Chen and 5 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International forum of allergy & rhinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04851964 (A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04851964 phase3completednot on this map

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT)

TypeinterventionalSponsorAstraZenecaRan2021 to 2024Enrolled416ConditionsChronic Rhinosinusitis With Nasal PolypsArmsExperimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joaquim MullolRhinology Unit & Smell Clinic, Department of Otorhinolaryngology, Hospital Clinic Barcelona, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Catalonia, Spain.ORCID https://orcid.org/0000-0003-3463-5007
Joseph K HanDepartment of Otolaryngology, Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, USA.
Tanya M LaidlawDivision of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Translational Immunology Research, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Claire HopkinsDepartment of Otolaryngology-Head and Neck Surgery, Guy's and St Thomas' Hospital, London, UK.ORCID https://orcid.org/0000-0003-3993-1569
Anju T PetersDivision of Allergy and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0003-0745-2379
Oliver PfaarDepartment of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps University of Marburg, Marburg, Germany.
Martin DesrosiersDivision of Otolaryngology, Head and Neck Surgery, Centre Hospitalier de L'Université de Montréal, University of Montreal, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0003-3774-2959
Stella E LeeDivision of Otolaryngology, Head and Neck Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Andrew P LaneDepartment of Otolaryngology, Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-6369-5469
Claudia ChenBiometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
Yun ChonGlobal Biostatistical Science, Amgen, Thousand Oaks, California, USA.
Sandhia S PonnarambilLate-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Andrew FosterRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
Andrew W LindsleyUS Medical Affairs, Amgen, Thousand Oaks, California, USA.
Christopher S AmbroseRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.ORCID https://orcid.org/0000-0003-4175-7336

Funding

Amgen Inc.AstraZeneca
6 · The paper itself

Abstract

backgroundLoss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health-related quality of life and posing a safety hazard.

methodsWAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Changes from baseline in biweekly mean Nasal Polyposis Symptom Diary (NPSD) loss of smell item, University of Pennsylvania Smell Identification Test (UPSIT), and 22-item Sino-Nasal Outcome Test (SNOT-22) loss of smell/taste item scores, as well as anosmia (UPSIT score ≤18) prevalence, were assessed over 52 weeks.

resultsAmong 408 patients (tezepelumab [n = 203]; placebo [n = 205]), significant improvements with tezepelumab versus placebo in NPSD loss of smell item, UPSIT, and SNOT-22 loss of smell/taste item scores were seen at week 4 (least-squares mean [LSM] treatment difference [95% CI]: -0.36 [-0.46, -0.27]; 6.03 [4.72, 7.34]; and -1.01 [-1.22, -0.80], respectively) and week 52 (-1.01 [-1.18, -0.83]; 9.50 [7.84, 11.16]; and -1.90 [-2.20, -1.61]); all nominal p < 0.0001. Between-treatment differences in daily NPSD loss of smell item score were evident from day 7 (LSM treatment difference: -0.08 [95% CI: -0.15, -0.02]; nominal p < 0.01). Improvements in NPSD loss of smell, UPSIT, and SNOT-22 loss of smell/taste item scores were observed across multiple prespecified subgroups. Anosmia prevalence was lower with tezepelumab than placebo at week 4 (43.0% [n/N = 64/149] vs. 80.3% [n/N = 106/132]) and week 52 (31.5% [n/N = 47/149] vs. 75.8% [n/N = 100/132]).

conclusionsTezepelumab provides early and sustained improvements in sense of smell among patients with uncontrolled CRSwNP.

Indexed as

Antibodies, Monoclonal, HumanizedNasal PolypsOlfaction DisordersRhinitisSinusitisSmellAdultAgedChronic DiseaseDouble-Blind MethodFemaleHumansMaleMiddle AgedQuality of LifeRhinosinusitisAntibodies, Monoclonal, Humanizedtezepelumabanosmiaanti‐TSLPbiologichyposmiamicrosmiasinonasalUPSIT

Identifiers

PMID41493192
PMCPMC13147228

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.